Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
基本信息
- 批准号:10553701
- 负责人:
- 金额:$ 95.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-02-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute Lung InjuryAcute Respiratory Distress SyndromeAffectAlveolarAlveolar CellAlveolar MacrophagesApoptosisBindingBiologyBlood capillariesBronchoscopyCalibrationCellsCitric Acid CycleClinical ResearchDataDevelopmentEmbryonic DevelopmentEndothelial CellsEndotheliumEnergy-Generating ResourcesEpithelial CellsEpitheliumFibrosisGlycolysisGoalsHealthHeartHumanHuman VolunteersInflammationInflammatoryInflammatory ResponseLifeLinkLungMacrophageMetabolicMetabolismMucinsPathologicPatientsPersonsPlayPneumoniaProteinsRecoveryResearch PersonnelResolutionRoleSialic AcidsSpecimenStable PopulationsSystemTechnologyTestingTissuesTransgenic Animalsalveolar epitheliumcell injuryinflammatory lung diseaseinjuredlung injurylung repairmonocytemultidisciplinaryneutrophilnovelprogramsreceptor bindingrecruitrepair functionrepairedself-renewalsialic acid binding Ig-like lectintissue repair
项目摘要
PROJECT SUMMARY
Acute inflammatory lung diseases affect over 450 million people worldwide each year. Pathologic hallmarks
include neutrophil accumulation, alveolar epithelial and endothelial cell injury, and loss of epithelial-capillary
integrity. For alveolar repair to occur, inflammation must be halted, debris and inflammatory cells removed,
injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of
these. The primary objective of this proposal is to create a Program in Lung Macrophage Biology that will
determine how lung macrophages are programmed to halt inflammation and promote alveolar repair.
A concept at the heart of the proposal is that of macrophage subsets. During health, the airspaces are
occupied by a stable population of resident alveolar macrophages (RAM) that arise during embryogenesis and
self-renew throughout life. RAMs remain during inflammation but are joined by recruited macrophages (RecM)
that mature from circulating monocytes. These RecM remain in the lungs until alveolar function is restored, and
then in most cases undergo apoptosis. However, in certain situations RecM escape apoptosis. We have shown
that this is associated with the development of fibrosis.
The precise roles played by RAMs vs RecM in the resolution of inflammation and promotion of tissue repair
remain largely unknown. However, our data suggest that their respective roles are very different. In this
context, the Program in Lung Macrophage Biology will explore 3 complementary themes. Theme 1 tests the
hypothesis that RecM apoptosis is essential for the resolution of inflammation and that delayed apoptosis leads
to fibrosis. The mechanisms that regulate the extrinsic apoptosis pathway and the intracellular proteins that
block it will be studied. Theme 2 tests the hypothesis that binding of airway-derived mucins to Siglecs (a class
of sialic acid-binding receptors with immunoinhibitory function) expressed on macrophages calibrates
macrophage inflammatory responses. Theme 3 provides a tight link with the other themes and explores how
cellular metabolism regulates macrophage inflammatory and pro-reparative functions and how it regulates
survival of macrophage subsets. In this context, we propose that RecM preferentially use glycolysis as an
energy source, whereas RAMs have increased utilization of the TCA cycle. HIF-1a is stabilized in RecM and is
viewed as a central metabolic regulator. The 3 themes are further linked by their focus on differential functions
of RAM vs RecM, the utilization of fresh human macrophages and shared use of cutting edge technologies.
The Program leverages a multidisciplinary team of highly accomplished investigators, novel transgenic animal
systems that we have developed, and a strong clinical research component. The latter includes whole human
lungs obtained from donors that died with ARDS, bronchoscopy specimens from patients with ARDS, and LPS
exposure studies with healthy human volunteers.
项目总结
全球每年有超过4.5亿人感染急性炎症性肺病。病理特征
包括中性粒细胞聚集,肺泡上皮和内皮细胞损伤,上皮毛细血管丢失
正直。要进行肺泡修复,必须停止炎症,清除碎片和炎症细胞,
损伤的组织细胞被替换,毛细血管屏障功能重建。巨噬细胞是所有
这些。这项提议的主要目标是创建一个肺巨噬细胞生物学计划,该计划将
确定肺巨噬细胞如何被编程来抑制炎症和促进肺泡修复。
该提案的核心概念是巨噬细胞亚群。在健康期间,空域是
由稳定的常驻肺泡巨噬细胞(RAM)种群占据,这些RAM在胚胎发育和
在一生中自我更新。RAM在炎症期间仍然存在,但会被招募的巨噬细胞(RecM)加入
从循环中的单核细胞中成熟。这些RECM保留在肺内,直到肺泡功能恢复,并且
然后,在大多数情况下会发生细胞凋亡。然而,在某些情况下,RECM逃脱了细胞凋亡。我们已经展示了
这与纤维化的发展有关。
RAMS和RECM在消退炎症和促进组织修复中的确切作用
在很大程度上仍然不为人知。然而,我们的数据表明,他们各自的角色非常不同。在这
在此背景下,肺巨噬细胞生物学计划将探索3个互补的主题。主题1测试
假设RECM细胞凋亡对于炎症的消退是必不可少的,并且延迟的细胞凋亡导致
到纤维化症。调控外源性细胞凋亡途径和细胞内蛋白的机制
我们将对其进行研究。主题2测试了呼吸道来源的粘蛋白与Siglecs(一类)结合的假设
具有免疫抑制功能的唾液酸结合受体)在巨噬细胞上表达
巨噬细胞炎症反应。主题3提供了与其他主题的紧密联系,并探讨了
细胞代谢调节巨噬细胞炎症和修复功能及其调节方式
巨噬细胞亚群的存活。在这种情况下,我们建议RecM优先使用糖酵解作为一种
能源,而公羊则增加了对三氯乙烷循环的利用。HIF-1a在RECM和IS中稳定
被视为中枢新陈代谢调节剂。这三个主题通过对不同功能的关注而进一步联系在一起
RAM与RecM的对比,新鲜人类巨噬细胞的利用以及尖端技术的共同使用。
该计划利用了一支由高度成功的研究人员组成的多学科团队,新型转基因动物
我们开发的系统和强大的临床研究组成部分。后者包括全人类
取自死于ARDS的供者的肺,ARDS患者的支气管镜标本,以及内毒素
对健康的人类志愿者进行暴露研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Janssen其他文献
William Janssen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Janssen', 18)}}的其他基金
Aspen Lung Conference: Bridging the Gap between Innate and Adaptive Immunity in the Lung
阿斯彭肺部会议:弥合肺部先天免疫和适应性免疫之间的差距
- 批准号:
10469141 - 财政年份:2022
- 资助金额:
$ 95.05万 - 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
- 批准号:
10335239 - 财政年份:2018
- 资助金额:
$ 95.05万 - 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
- 批准号:
10225232 - 财政年份:2018
- 资助金额:
$ 95.05万 - 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
- 批准号:
10094076 - 财政年份:2018
- 资助金额:
$ 95.05万 - 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
- 批准号:
8528053 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
- 批准号:
8460822 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
Hif-1 alpha metabolically reprograms recruited alveolar macrophages to promote lung repair
Hif-1 α 通过代谢重新编程招募的肺泡巨噬细胞以促进肺修复
- 批准号:
9309186 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
- 批准号:
8661268 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
- 批准号:
8297328 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
- 批准号:
8830993 - 财政年份:2012
- 资助金额:
$ 95.05万 - 项目类别:
相似海外基金
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8429041 - 财政年份:2011
- 资助金额:
$ 95.05万 - 项目类别:
Analysis of extravascular lung water dynamics and exhaustive evaluation of pulmonary epithelial metabolites to establish a novel therapeutic approach for acute lung injury/ acute respiratory distress syndrome
分析血管外肺水动力学和详尽评估肺上皮代谢物,以建立急性肺损伤/急性呼吸窘迫综合征的新治疗方法
- 批准号:
22592023 - 财政年份:2010
- 资助金额:
$ 95.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
OBSERVATIONAL STUDY OF ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
急性肺损伤的观察性研究
- 批准号:
7603766 - 财政年份:2007
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8602427 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8602351 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8654999 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8844846 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8328484 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8328493 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
- 批准号:
8020428 - 财政年份:2005
- 资助金额:
$ 95.05万 - 项目类别:














{{item.name}}会员




